Clinical study of chemotherapy-induced cardiotoxicity of epirubicin associated with dexrazoxane and liposomal doxorubicin

Objective To observe the effect of epirubicin combined with dexrazoxane and more flexible than the protective effect of liposomal doxorubicin on cardiac toxicity induced by chemotherapy. Methods 96 cases of postoperative breast cancer patients were divided into dexrazoxane group, liposomal doxorubicin group and control group, adjuvant chemotherapy in three patients were treated with anthracycline-based after 4 cycles, the abnormal rate of ECG monitoring in each period, left ventricle ejection fraction (LVEF color Doppler ultrasound), fractional shortening (SF) to evaluate the heart function. Results in the control group after chemotherapy, the abnormal rate of ECG was highest, dexrazoxane group, doxorubicin can significantly reduce the abnormal rate of ECG was star liposome group, and from the 1 cycle of chemotherapy showed protective effect on the heart; and the changes of LVEF and SF in three patients before and after chemotherapy group had no statistical differences (P0.05). Conclusion Epirubicin chemotherapy with DEX or the use of liposomal doxorubicin on reducing anthracycline cardiotoxicity is safe and effective.